|Code No.||K0142-6||Print out|
|Anti-PSMA (Human) mAb-Biotin|
|Size||50 µg/50 µL|
|Availability (in Japan)||1-9
（In Japan at 00:05, Jan 29, 2020 in JST）
|Applications||FCM 3-5 µg/mL (final concentration)
ELISA Can be used.
|LNCaP cell homogenate|
|Reactivity [Gene ID]||
|Storage buffer||1 mg/mL in PBS/1% BSA/0.1% ProClin 150|
|Alternative names||FOLH1, folate hydrolase (prostate-specific membrane antigen) 1|
PSMA is a type II transmembrane protein expressed at high levels in prostate cancer and in tumor-associated neovasculature. PSMA is also known as a glutamate carboxypeptidase II (EC 184.108.40.206) that hydrolyzes the neuropeptide, N-acetyl-L-aspartyl-L-glutamate, releasing glutamate, the dominant excitatory neurotransmitter/neuromodulator of the mammalian central nervous system. The ability of PSMA to liberate g-glutamate may allow the removal of glutamate residues from dietary folates, which are unable to be transported into cells in their poly-g-glutamate form. Overexpression of PSMA in prostate cancer cells may represent an advantageous adaptation that allows the uptake of folates required for rapid division. The exopeptidase activity exhibited by PSMA and its high-level overexpression in prostate cancer cells make it a potential target for selective anticancer therapy and prodrug activation.
|Related products||K0142-3 Anti-PSMA (Human) mAb
K0142-4 Anti-PSMA (Human) mAb-FITC
K0142-5 Anti-PSMA (Human) mAb-PE
|Product category||:CancerResearch area:Cancer Cell surface antigens Exosomes|